JP2011503210A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503210A5 JP2011503210A5 JP2010534263A JP2010534263A JP2011503210A5 JP 2011503210 A5 JP2011503210 A5 JP 2011503210A5 JP 2010534263 A JP2010534263 A JP 2010534263A JP 2010534263 A JP2010534263 A JP 2010534263A JP 2011503210 A5 JP2011503210 A5 JP 2011503210A5
- Authority
- JP
- Japan
- Prior art keywords
- piperidin
- yloxy
- alkyl
- phenyl
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 hydrate Chemical class 0.000 claims description 257
- 150000001875 compounds Chemical class 0.000 claims description 123
- 125000000217 alkyl group Chemical group 0.000 claims description 61
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 35
- 125000001072 heteroaryl group Chemical group 0.000 claims description 34
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 229910052799 carbon Inorganic materials 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 23
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 22
- 125000004122 cyclic group Chemical group 0.000 claims description 19
- 150000001204 N-oxides Chemical class 0.000 claims description 17
- 239000000651 prodrug Substances 0.000 claims description 17
- 229940002612 prodrug Drugs 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000012453 solvate Substances 0.000 claims description 17
- 125000001188 haloalkyl group Chemical group 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 10
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 7
- 125000005605 benzo group Chemical group 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 150000003857 carboxamides Chemical class 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- MCLGXPUTSWJSRB-UHFFFAOYSA-N 1-(pyridin-4-ylmethyl)-n-[5-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]oxy-2,3-dihydro-1h-inden-1-yl]piperidin-4-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1N1CCC(OC=2C=C3CCC(C3=CC=2)NC2CCN(CC=3C=CN=CC=3)CC2)CC1 MCLGXPUTSWJSRB-UHFFFAOYSA-N 0.000 claims description 2
- IIYPLRFMIACDPN-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-n-[5-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]oxy-2,3-dihydro-1h-inden-1-yl]piperidin-4-amine Chemical compound C1=CC(F)=CC=C1CN1CCC(NC2C3=CC=C(OC4CCN(CC4)C=4C=CC(=CC=4)C(F)(F)F)C=C3CC2)CC1 IIYPLRFMIACDPN-UHFFFAOYSA-N 0.000 claims description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- GCWSPRDNKSEPKJ-UHFFFAOYSA-N CC1C=CC(=CN1C2CCN(CC2)CC3=CN(C=N3)C(C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6)OC7CCN(CC7)C8=CC=C(C=C8)C(F)(F)F Chemical compound CC1C=CC(=CN1C2CCN(CC2)CC3=CN(C=N3)C(C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6)OC7CCN(CC7)C8=CC=C(C=C8)C(F)(F)F GCWSPRDNKSEPKJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims description 2
- AVRWEULSKHQETA-UHFFFAOYSA-N Thiophene-2 Chemical compound S1C=2CCCCCC=2C(C(=O)OC)=C1NC(=O)C1=C(F)C(F)=C(F)C(F)=C1F AVRWEULSKHQETA-UHFFFAOYSA-N 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims description 2
- ZTFZEMAQQLKFEQ-UHFFFAOYSA-N n-[1-(pyridin-4-ylmethyl)piperidin-4-yl]-6-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]oxypyridine-2-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1N1CCC(OC=2N=C(C=CC=2)C(=O)NC2CCN(CC=3C=CN=CC=3)CC2)CC1 ZTFZEMAQQLKFEQ-UHFFFAOYSA-N 0.000 claims description 2
- JGGUDZHAKXSMBF-UHFFFAOYSA-N n-[5-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]oxy-2,3-dihydro-1h-inden-1-yl]piperidin-4-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1N1CCC(OC=2C=C3CCC(C3=CC=2)NC2CCNCC2)CC1 JGGUDZHAKXSMBF-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- KXNHURZRBCWTFV-UHFFFAOYSA-N tert-butyl 4-[[5-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]oxy-2,3-dihydro-1h-inden-1-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1C2=CC=C(OC3CCN(CC3)C=3C=CC(=CC=3)C(F)(F)F)C=C2CC1 KXNHURZRBCWTFV-UHFFFAOYSA-N 0.000 claims description 2
- RTJCPJPIPFHECW-UHFFFAOYSA-N tert-butyl 4-[[6-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]oxypyridin-3-yl]sulfonylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NS(=O)(=O)C(C=N1)=CC=C1OC1CCN(C=2C=CC(=CC=2)C(F)(F)F)CC1 RTJCPJPIPFHECW-UHFFFAOYSA-N 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- DFWJSMFBORLYJK-UHFFFAOYSA-N O=C(C1=CC(C=CC=C2)=C2S1)NOC(CC1)CCN1C1=CC=C(C(F)(F)F)C=C1 Chemical compound O=C(C1=CC(C=CC=C2)=C2S1)NOC(CC1)CCN1C1=CC=C(C(F)(F)F)C=C1 DFWJSMFBORLYJK-UHFFFAOYSA-N 0.000 claims 1
- NKFLEFWUYAUDJV-UHFFFAOYSA-N pyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CC=CN=C1 NKFLEFWUYAUDJV-UHFFFAOYSA-N 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- BYHWWOPUEYHTSB-UHFFFAOYSA-N 4-[[4-[[5-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]oxy-2,3-dihydro-1h-inden-1-yl]amino]piperidin-1-yl]methyl]benzonitrile Chemical compound C1=CC(C(F)(F)F)=CC=C1N1CCC(OC=2C=C3CCC(C3=CC=2)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 BYHWWOPUEYHTSB-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98872107P | 2007-11-16 | 2007-11-16 | |
| US60/988,721 | 2007-11-16 | ||
| US99055407P | 2007-11-27 | 2007-11-27 | |
| US99055807P | 2007-11-27 | 2007-11-27 | |
| US60/990,554 | 2007-11-27 | ||
| US60/990,558 | 2007-11-27 | ||
| US99118907P | 2007-11-29 | 2007-11-29 | |
| US60/991,189 | 2007-11-29 | ||
| US1392407P | 2007-12-14 | 2007-12-14 | |
| US61/013,924 | 2007-12-14 | ||
| PCT/US2008/083801 WO2009065131A1 (en) | 2007-11-16 | 2008-11-17 | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011503210A JP2011503210A (ja) | 2011-01-27 |
| JP2011503210A5 true JP2011503210A5 (enExample) | 2012-12-20 |
| JP5544296B2 JP5544296B2 (ja) | 2014-07-09 |
Family
ID=40352415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010534263A Expired - Fee Related JP5544296B2 (ja) | 2007-11-16 | 2008-11-17 | 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8119809B2 (enExample) |
| EP (1) | EP2231600B1 (enExample) |
| JP (1) | JP5544296B2 (enExample) |
| KR (1) | KR101573091B1 (enExample) |
| CN (1) | CN101910131B (enExample) |
| AU (3) | AU2008322426C1 (enExample) |
| BR (1) | BRPI0820171B8 (enExample) |
| CA (1) | CA2705947C (enExample) |
| EA (1) | EA019509B1 (enExample) |
| ES (1) | ES2552733T3 (enExample) |
| IL (1) | IL205624A (enExample) |
| MX (2) | MX2010005298A (enExample) |
| NZ (1) | NZ585298A (enExample) |
| WO (1) | WO2009065131A1 (enExample) |
| ZA (1) | ZA201003412B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008083124A1 (en) | 2006-12-28 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
| JP5544296B2 (ja) | 2007-11-16 | 2014-07-09 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物 |
| ES2553340T3 (es) * | 2007-12-12 | 2015-12-07 | Rigel Pharmaceuticals, Inc. | Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos |
| JP5658138B2 (ja) * | 2008-04-23 | 2015-01-21 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 代謝障害の処置のためのカルボキサミド化合物 |
| HUE025013T2 (hu) | 2009-01-12 | 2016-04-28 | Pfizer Ltd | Szulfonamid-származékok |
| CN102365275B (zh) | 2009-01-28 | 2014-09-24 | 里格尔药品股份有限公司 | 羧酰胺化合物及其使用方法 |
| SG176628A1 (en) | 2009-06-05 | 2012-01-30 | Link Medicine Corp | Aminopyrrolidinone derivatives and uses thereof |
| CN102666485A (zh) * | 2009-09-21 | 2012-09-12 | 霍夫曼-拉罗奇有限公司 | 烯烃羟吲哚衍生物及其用于治疗肥胖症，糖尿病和高脂血症的应用 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| JPWO2011115106A1 (ja) * | 2010-03-16 | 2013-06-27 | 国立大学法人 東京大学 | 擬似運動療法のための医薬 |
| WO2011123681A1 (en) * | 2010-03-31 | 2011-10-06 | Rigel Pharmaceuticals, Inc. | Methods for using carboxamide, sulfonamide and amine compounds |
| JPWO2011142359A1 (ja) * | 2010-05-10 | 2013-07-22 | 日産化学工業株式会社 | スピロ化合物及びアディポネクチン受容体活性化薬 |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| US9079880B2 (en) | 2010-07-07 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| US8697911B2 (en) | 2010-07-07 | 2014-04-15 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| JP5872552B2 (ja) | 2010-07-09 | 2016-03-01 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化学化合物 |
| KR101764952B1 (ko) | 2010-07-29 | 2017-08-03 | 리겔 파마슈티칼스, 인크. | Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법 |
| US9000154B2 (en) | 2010-10-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| US9005909B2 (en) | 2011-01-06 | 2015-04-14 | Rigel Pharmaceuticals, Inc. | Whole blood assay for measuring AMPK activation |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9409884B2 (en) * | 2012-02-01 | 2016-08-09 | Rigel Pharmaceuticals, Inc. | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| JP6233855B2 (ja) * | 2012-08-08 | 2017-11-22 | ノバルティス・ティーアゲズントハイト・アクチェンゲゼルシャフトＮｏｖａｒｔｉｓ Ｔｉｅｒｇｅｓｕｎｄｈｅｉｔ Ａｇ | 殺虫剤としての置換されたアジン類 |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| EP2970177A1 (en) | 2013-03-15 | 2016-01-20 | Pfizer Inc. | Indole compounds that activate ampk |
| KR102318727B1 (ko) | 2013-07-31 | 2021-10-28 | 노파르티스 아게 | 1,4-이치환된 피리다진 유사체 및 smn-결핍-관련 상태를 치료하기 위한 그의 용도 |
| US20160214967A1 (en) * | 2013-09-30 | 2016-07-28 | The University Of Tokyo | Activator of adiponectin receptor |
| WO2016091042A1 (zh) * | 2014-12-08 | 2016-06-16 | 江苏恒瑞医药股份有限公司 | 吡啶甲酰胺类衍生物、其制备方法及其在医药上的应用 |
| CN114206851B (zh) * | 2019-04-26 | 2025-02-11 | 默沙东有限责任公司 | 可用于制备(2s,5r)-7-氧代-n-哌啶-4-基-6-(硫酸基)-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺的中间体的制备方法 |
| WO2022072397A1 (en) | 2020-09-30 | 2022-04-07 | Bioverativ Therapeutics Inc. | Ampk activators and methods of use thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8820115D0 (en) | 1988-08-24 | 1988-09-28 | Ici Plc | Insecticidal compounds |
| US6137002A (en) | 1993-07-22 | 2000-10-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
| EA001437B1 (ru) | 1996-03-28 | 2001-02-26 | Глаксо Груп Лимитед | Производные пирролопирролона в качестве ингибиторов нейтрофильной эластазы |
| GB9715584D0 (en) | 1997-07-23 | 1997-10-01 | Eisai Co Ltd | Compounds |
| DE19738615A1 (de) | 1997-09-04 | 1999-03-11 | Clariant Gmbh | Neue Lichtschutzmittel auf Basis von sterisch gehinderten Aminen |
| US6589954B1 (en) | 1998-05-22 | 2003-07-08 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
| AU772477B2 (en) | 1998-08-28 | 2004-04-29 | Scios Inc. | Inhibitors of p38-alpha kinase |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| DK1218380T3 (da) | 1999-10-08 | 2004-03-15 | Gruenenthal Gmbh | Bicykliske imidazo-3-yl-aminoderivater substitueret i seksledsringen |
| US6436965B1 (en) | 2000-03-02 | 2002-08-20 | Merck Frosst Canada & Co. | PDE IV inhibiting amides, compositions and methods of treatment |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| EP1415987B1 (en) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
| JP2005500996A (ja) | 2001-05-10 | 2005-01-13 | アボット ゲーエムベーハー ウント カンパニー カーゲー | アリールスルホンアミドエーテルおよびそれの使用方法 |
| BR0212123A (pt) | 2001-08-24 | 2004-07-20 | Upjohn Co | 7-aza[2.2.1]biciclo-heptanos substituìdos com arila para o tratamento de doenças |
| EP1425286B1 (en) | 2001-09-12 | 2007-02-28 | Pharmacia & Upjohn Company LLC | Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases |
| US6858613B2 (en) | 2002-02-19 | 2005-02-22 | Pfizer Inc. | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease |
| WO2003072578A1 (en) | 2002-02-20 | 2003-09-04 | Pharmacia & Upjohn Company | Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
| AU2003245669A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
| CA2493457A1 (en) * | 2002-07-24 | 2004-01-29 | Tularik Inc. | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| RU2005118407A (ru) | 2002-12-13 | 2006-03-10 | СмитКлайн Бичем Корпорейшн (US) | Производные пиперидина в качестве антагонистов ccr5 |
| US7208491B2 (en) | 2003-02-07 | 2007-04-24 | Hoffmann-La Roche Inc. | N-monoacylated o-phenylenediamines |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| GB0314054D0 (en) | 2003-06-17 | 2003-07-23 | Pfizer Ltd | Amide derivatives as selective serotonin re-uptake inhibitors |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| WO2005020921A2 (en) | 2003-08-29 | 2005-03-10 | Exelixis, Inc. | C-kit modulators and methods of use |
| US7196100B2 (en) | 2003-12-12 | 2007-03-27 | Eli Lilly And Company | Opioid receptor antagonists |
| US7544803B2 (en) | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| RU2417225C2 (ru) * | 2004-03-25 | 2011-04-27 | Мемори Фармасьютиклз Корпорейшн | Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение |
| PE20060315A1 (es) | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
| CA2566526C (en) * | 2004-06-02 | 2012-10-23 | F. Hoffmann-La Roche Ag | Naphthaline derivatives useful as histamine-3-receptor ligands |
| ES2306170T3 (es) * | 2004-06-21 | 2008-11-01 | F. Hoffmann-La Roche Ag | Derivados de indol como antagonistas redeptores de histamina. |
| WO2006038594A1 (ja) * | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| MX2007004465A (es) | 2004-10-19 | 2007-05-07 | Hoffmann La Roche | Derivados de quinolina. |
| CA2584413A1 (en) | 2004-10-29 | 2006-05-04 | Astrazeneca Ab | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
| AU2005301568B2 (en) | 2004-11-08 | 2011-06-09 | Msd K.K. | Novel fused imidazole derivative |
| CA2588517A1 (en) | 2004-12-01 | 2006-06-08 | Devgen N.V. | 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family |
| US20080207634A1 (en) | 2004-12-17 | 2008-08-28 | Kristjan Gudmundsson | Chemical Compounds |
| AP2334A (en) | 2004-12-17 | 2011-12-06 | Glenmark Pharmaceuticals Sa | Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders. |
| GB0428235D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
| US20060187891A1 (en) | 2005-02-24 | 2006-08-24 | Jussi-Pekka Sairanen | Provision of services in a communication system |
| US7998974B2 (en) | 2005-03-03 | 2011-08-16 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| MX2007011234A (es) | 2005-03-14 | 2007-11-12 | Transtech Pharma Inc | Derivados de benzazol, composiciones y metodos de uso en la forma de inhibidores de b-secretasa. |
| WO2006101434A1 (en) | 2005-03-22 | 2006-09-28 | Astrazeneca Ab | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS |
| GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
| EP1907376A2 (en) | 2005-07-05 | 2008-04-09 | Aryx Therapeutics, Inc. | Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| KR20080048550A (ko) * | 2005-09-23 | 2008-06-02 | 메모리 파마슈티칼스 코포레이션 | 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸,피라졸로피리딘, 이소티아졸로피리딘, 및 이들의 제법 및용도 |
| WO2007063000A1 (en) | 2005-11-30 | 2007-06-07 | F. Hoffmann-La Roche Ag | 5-substituted indole-2-carboxamide derivatives |
| WO2007062999A2 (en) | 2005-11-30 | 2007-06-07 | F. Hoffmann-La Roche Ag | 1,5-substituted indol-2-yl amide derivatives |
| EP1968967B1 (en) | 2005-11-30 | 2011-04-27 | F. Hoffmann-La Roche AG | 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as h3 modulators |
| JP2009521451A (ja) * | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | ヒスタミンｈ３アンタゴニストとして有用な置換アニリン誘導体 |
| WO2007087548A2 (en) | 2006-01-25 | 2007-08-02 | Smithkline Beecham Corporation | Chemical compounds |
| AR059197A1 (es) | 2006-01-25 | 2008-03-19 | Smithkline Beecham Corp | Derivados de indazolo piridina para el tratamiento de hiv |
| US20090036429A1 (en) * | 2006-02-17 | 2009-02-05 | Ohler Norman E | Hydroxypiperidine Derivatives and Uses Thereof |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| EP2463283B1 (en) | 2006-04-20 | 2014-06-11 | Pfizer Products Inc. | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases |
| CA2651072A1 (en) * | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| CA2654792A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| JP2009539885A (ja) | 2006-06-13 | 2009-11-19 | メルク フロスト カナダ リミテツド | ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのアザシクロペンタン誘導体 |
| TW200821303A (en) | 2006-08-08 | 2008-05-16 | Speedel Experimenta Ag | Organic compounds |
| WO2008083124A1 (en) * | 2006-12-28 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
| WO2008133975A1 (en) * | 2007-04-26 | 2008-11-06 | Avalon Pharmaceuticals | Multi-ring compounds and uses thereof |
| US8299057B2 (en) * | 2007-07-20 | 2012-10-30 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
| JP5544296B2 (ja) | 2007-11-16 | 2014-07-09 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物 |
| ES2553340T3 (es) * | 2007-12-12 | 2015-12-07 | Rigel Pharmaceuticals, Inc. | Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos |
| JP2011516557A (ja) * | 2008-04-07 | 2011-05-26 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｇｐｒ１１９活性のモジュレーターとしての化合物および組成物 |
| JP5658138B2 (ja) | 2008-04-23 | 2015-01-21 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 代謝障害の処置のためのカルボキサミド化合物 |
| JP2010090067A (ja) * | 2008-10-09 | 2010-04-22 | Taisho Pharmaceutical Co Ltd | 含窒素複素環誘導体 |
-
2008
- 2008-11-17 JP JP2010534263A patent/JP5544296B2/ja not_active Expired - Fee Related
- 2008-11-17 EA EA201070619A patent/EA019509B1/ru not_active IP Right Cessation
- 2008-11-17 CA CA2705947A patent/CA2705947C/en active Active
- 2008-11-17 MX MX2010005298A patent/MX2010005298A/es active IP Right Grant
- 2008-11-17 ES ES08848677.4T patent/ES2552733T3/es active Active
- 2008-11-17 US US12/272,581 patent/US8119809B2/en active Active
- 2008-11-17 KR KR1020107013166A patent/KR101573091B1/ko not_active Expired - Fee Related
- 2008-11-17 MX MX2014005186A patent/MX382569B/es unknown
- 2008-11-17 AU AU2008322426A patent/AU2008322426C1/en not_active Ceased
- 2008-11-17 WO PCT/US2008/083801 patent/WO2009065131A1/en not_active Ceased
- 2008-11-17 BR BRPI0820171A patent/BRPI0820171B8/pt not_active IP Right Cessation
- 2008-11-17 NZ NZ585298A patent/NZ585298A/xx not_active IP Right Cessation
- 2008-11-17 CN CN200880124960.1A patent/CN101910131B/zh not_active Expired - Fee Related
- 2008-11-17 EP EP08848677.4A patent/EP2231600B1/en not_active Not-in-force
-
2010
- 2010-05-09 IL IL205624A patent/IL205624A/en active IP Right Grant
- 2010-05-14 ZA ZA2010/03412A patent/ZA201003412B/en unknown
-
2012
- 2012-01-11 US US13/348,380 patent/US8569340B2/en not_active Expired - Fee Related
-
2013
- 2013-10-14 US US14/053,325 patent/US9174964B2/en active Active
-
2014
- 2014-05-13 AU AU2014202572A patent/AU2014202572B2/en not_active Ceased
-
2017
- 2017-04-27 AU AU2017202766A patent/AU2017202766B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011506480A5 (enExample) | ||
| JP2010514788A5 (enExample) | ||
| ES2552733T3 (es) | Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos | |
| JP2011527665A5 (enExample) | ||
| CA2798360C (en) | Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same | |
| EP1396487B1 (en) | Phenylpyridine carbonyl piperazine derivative | |
| JP4719745B2 (ja) | カリウムチャンネル阻害剤 | |
| JP2013532692A5 (enExample) | ||
| JP2012512255A5 (enExample) | ||
| TW200823188A (en) | Certain chemical entities, compositions, and methods | |
| NZ588652A (en) | Carboxamide compounds for the treatment of metabolic disorders | |
| KR20180073685A (ko) | 신경계 질환을 치료하기 위한, 무스카린성 수용체 4 (m4) 길항제로서의 n-[2-(1-벤질피페리딘-4-일)에틸]-4-(피라진-2-일)-피페라진-1-카르복스아미드 유도체 및 관련된 화합물 | |
| RU2008116313A (ru) | Диарилминсодержащие соединения, композиции и их примеение в качестве модуляторов рецепторов с-кit | |
| JP2006298893A5 (enExample) | ||
| KR20120049940A (ko) | 키나제 억제제로서의 헤테로아릴 화합물 | |
| JP2016501240A5 (enExample) | ||
| RU2005122932A (ru) | Производные бензазепина для лечения неврологических нарушений | |
| RU2018138047A (ru) | Гетероциклические вещества - агонисты gpr119 | |
| JP2013530947A (ja) | Ｇｐｒ１１９調節薬としてのピペリジニル置換ラクタム | |
| JP2014501269A5 (enExample) | ||
| KR20120092586A (ko) | 증식성 질환의 치료에 유용한 비피리딘 | |
| KR20120076352A (ko) | 증식성 질환의 치료에 유용한 피라지닐피리딘 | |
| JP2007532596A5 (enExample) | ||
| KR102217285B1 (ko) | 신규한 3,4-다이하이드로-2h-이소퀴놀린-1-온 및 2,3-다이하이드로-이소인돌-1-온 화합물 | |
| CZ186698A3 (cs) | Substituované piperidiny, jako antagonisté tachykininu |